Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.270
+0.300 (30.93%)
At close: Apr 21, 2025, 4:00 PM
1.160
-0.110 (-8.66%)
After-hours: Apr 21, 2025, 7:36 PM EDT
Evogene Revenue
In the year 2024, Evogene had annual revenue of $8.51M with 50.90% growth. Evogene had revenue of $1.61M in the quarter ending December 31, 2024, with 178.72% growth.
Revenue (ttm)
$8.51M
Revenue Growth
+50.90%
P/S Ratio
0.87
Revenue / Employee
$72,744
Employees
117
Market Cap
7.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.51M | 2.87M | 50.90% |
| Dec 31, 2023 | 5.64M | 3.97M | 236.72% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
EVGN News
- 16 hours ago - ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio - PRNewsWire
- 6 weeks ago - Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Evogene Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 weeks ago - Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - PRNewsWire
- 2 months ago - Evogene Schedules Fourth Quarter 2024 Financial Results Release - PRNewsWire
- 2 months ago - AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease - PRNewsWire
- 5 months ago - Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Evogene Reports Third Quarter 2024 Financial Results - PRNewsWire